17968-81-9 Purity
---
If you have any other questions or need other size, please get a quote.
Reference: [1] Synthetic Communications, 2014, vol. 44, # 3, p. 346 - 351
[2] Tetrahedron, 2010, vol. 66, # 4, p. 962 - 968
Reference: [1] Patent: EP1477481, 2004, A1, . Location in patent: Page 20
Reference: [1] Patent: EP1477481, 2004, A1, . Location in patent: Page 19
Reference: [1]Journal of labelled compounds and radiopharmaceuticals,2005,vol. 48,p. 829 - 843
Reference: [1]Seimbille, Yann; Phelps, Michael E.; Czernin, Johannes; Silverman, Daniel H. S.
[Journal of labelled compounds and radiopharmaceuticals, 2005, vol. 48, # 11, p. 829 - 843]
Reference: [1]Nakamura, Hiroyuki; Onagi, Shinya
[Tetrahedron Letters, 2006, vol. 47, # 15, p. 2539 - 2542]
[2]Zhang, Gengzhen; Zha, Linlin
[Research on Chemical Intermediates, 2013, vol. 39, # 6, p. 2303 - 2309]
[3]Current Patent Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION - US2011/288086, 2011, A1
Location in patent: Page/Page column 29
[4]Current Patent Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.; CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION - EP2592083, 2013, A1
Location in patent: Paragraph 0261
[5]Chen, Zhe-Sheng; Dai, Qing-Qing; Li, Guo-Bo; Liu, Hong-Min; Liu, Hui; Wang, Bo; Wang, Shaomeng; Yu, Bin; Yuan, Shuo; Zhang, Jing-Ya; Zhang, Xiao-Nan; Zuo, Jia-Hui
[Journal of Medicinal Chemistry, 2021, vol. 64, # 19, p. 14895 - 14911]
* For details of the synthesis route, please refer to the original source to ensure accuracy.